Clinical Trial Technology Editorial

  1. Technology Advancements Spur Adoption Of Virtual Trials 1/17/2020

    Patient recruitment and retention in clinical trials has long been an issue for pharma companies. This results in many trials being delayed and even canceled. One recent advancement that could help with both recruitment and retention is virtual (decentralized) trials.

  2. Janssen Uses Geofencing To Monitor Clinical Trial Patients 12/17/2019

    A new patient-facing technology being tested by Janssen will be used to passively track hospitalization events based on the location services available from the smartphone of a patient.

  3. Acquiring And Implementing Innovation In The Pharmaceutical Industry 12/5/2019

    Pravin Jadhav has spent his entire career in the world of drug development. He is currently the Senior Director of Applied Innovation at Otsuka. Jadhav was a featured speaker at the recent CNS Summit in Boca Raton, and we took that opportunity to talk to him about innovation in the pharmaceutical industry, and how companies can best acquire and implement new solutions. 

  4. Analyzing The Top Clinical Trial Technology Trends 11/29/2019

    Technology plays a critical role in drug development and the R&D value chain by revolutionizing clinical trials and decreasing the failure rate. Though the supply of technology has been increasing and regulation of innovative methods is easing, pharmaceutical companies have been slow to use the emerging technologies, due to the ambiguity prevailing around this space and a highly fragmented supply market. This article outlines the key technologies that have a high impact across trial phases.

  5. What Exactly Is A Virtual Clinical Trial? 11/21/2019

    Oracle Health Sciences and the CNS Summit have released a research report on the use of virtual components (patient-facing technologies) in clinical trials. The findings are the result of focus group interviews and supplementary research with key stakeholders involved with clinical trials.

  6. The Myth Of Disruptive Innovation In Clinical Trials: Time For A More Disciplined Approach 11/21/2019

    At the outset, let me state for the record that I’m a big advocate for change. My threshold for accepting “that’s the way we’ve always done things” is actually quite low. But I confess that I’m getting a bit dizzy, dismayed, and, to be frank, disappointed with all the so-called “disruptive innovation” taking place in the industry. First and foremost, I don't really think that anything taking place really qualifies as disruptive.

  7. Former Novartis CEO: Cell And Gene Therapies Will Drive Innovation 11/19/2019

    Joe Jimenez joined Novartis as division head of Consumer Health. A few months later, he was asked to run the pharmaceutical division. Shortly after his promotion to CEO, Novartis was the first company to pursue a CAR T therapy. Today, Jimenez marvels at the innovation taking place in the industry, and believes cell and gene therapies will drive future development. 

  8. Will Virtual Trials Mean The End Of CROs? 11/4/2019

    Virtual trials are growing in acceptance. The patient-centric aspect of these trials makes them easier to recruit and retain patients and accelerate timelines, while also providing patient data to researchers in real time. But will virtual trials also mean the end of CROs?

  9. Driving Innovation: Blockchain Adoption For Clinical Trials Optimization 10/31/2019

    Pharmaceutical companies and research institutions are feeling the pressure to reduce the time, financial, and other resource costs associated with conducting clinical trials. With the influx of emerging applications for technologies such as machine learning, robotics and automation, and blockchain and other distributed ledger technologies (DLTs), many see a new path to more efficient and effective processes that can address the challenges faced today.

  10. Less Cumbersome Trials Will Reduce Clinical Costs & Timelines 10/28/2019

    Antony Loebel, president and CEO for Sunovion Pharmaceuticals, will be a featured speaker at the upcoming 2019 CNS Summit. In this Q&A, Loebel discusses CNS innovation, balancing the needs of clinical stakeholders, and the biggest changes we can expect over the next 10 years.